[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602059":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":47,"locations":57,"responsibleParty":73,"collaborators":52,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":52,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":52,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":59,"whyStopped":52,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Propofol group","ACTIVE_COMPARATOR","Anesthesia induction (2-3 mg\u002Fkg) + Anesthesia maintenance (6-10 mg\u002Fkg\u002Fh)",[13],"Drug: Propofol",{"label":15,"type":16,"description":17,"interventionNames":18},"Remimazolam group","EXPERIMENTAL","Anesthesia induction (0.3-0.5 mg\u002Fkg) + Anesthesia maintenance (1-3 mg\u002Fkg\u002Fh)",[19],"Drug: Remimazolam",{"label":21,"type":16,"description":22,"interventionNames":23},"Ciprofol group","Anesthesia induction (0.4-0.5 mg\u002Fkg) + Anesthesia maintenance (0.8-1.2 mg\u002Fkg\u002Fh)",[24],"Drug: Ciprofol",[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Remimazolam","remimazolam induction (0.3-0.5 mg\u002Fkg) + maintenance (1-3 mg\u002Fkg\u002Fh)",[15],[32],"Remi",{"type":27,"name":34,"description":11,"armGroupLabels":35,"otherNames":36},"Propofol",[9],[37],"PRO",{"type":27,"name":39,"description":22,"armGroupLabels":40,"otherNames":41},"Ciprofol",[21],[42],"CIP",[44],{"name":45,"affiliation":5,"role":46},"Mujun Chang","STUDY_DIRECTOR",[48,54],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},"Pu Zhou","CONTACT","02783663625",null,"tongjihlunli@163.com",{"name":55,"role":50,"phone":51,"phoneExt":52,"email":56},"Aihua Du","70663307@qq.com",[58],{"facility":5,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":66,"coordinates":67},"Point",[68,69],114.26667,30.58333,{"lat":69,"lon":68},[72],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":52,"oldOrganization":52},"PRINCIPAL_INVESTIGATOR","aijun xu","Professor","100602059","phase-4-effects-of-remimazolam-and-ciprofol-tiva-on-prae-in-pediatric-tonsillectomy-and-adenoidectomy-100602059",false,"NCT07118579","Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy","Effects of Remimazolam and Ciprofol Total Intravenous Anesthesia on Perioperative Respiratory Adverse Events in Pediatric Tonsillectomy and Adenoidectomy: A Randomized Controlled Study","Inclusion Criteria:\n\n* Aged 2-12 years\n* ASA physical status I-II\n* Body mass index (BMI): 14-28 kg\u002Fm²\n* Scheduled for elective tonsillectomy with or without adenoidectomy\n* Signed informed consent by legal guardian(s) and assent by children (≥8 years old)\n\nExclusion Criteria:\n\n* History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)\n* Previous episodes of significant PRAEs\n* Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)\n* Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic\u002Frenal function\n* Preoperative moderate-to-severe respiratory infections requiring surgery postponement\n* Recent participation in other clinical trials","ALL","2 Years","12 Years",{"count":88,"type":89},114,"ESTIMATED","INTERVENTIONAL",[92],"PHASE4","To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.",[95],"Tonsillectomy With or Without Adenoidectomy",[28,39,97,98],"TIVA","PRAE","2025-11-17",{"date":101,"type":102},"2025-11-21","ACTUAL",{"date":104,"type":102},"2025-09-23",{"date":106,"type":89},"2026-08",{"name":5,"class":6},1]